CITIUS ONCOLOGY INC(CTOR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CTOR CITIUS ONCOLOGY INC

盘后交易 03-26 16:00:19 EDT

0.5410

-0.0370

-6.40%

最高0.5800	最低0.5200	成交量18.88万
今开0.5800	昨收0.5780	日振幅10.38%
总市值4,776万	流通市值666.57万	总股本8,828万
成交额10.12万	换手率1.53%	流通股本1,232万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CTOR","market":"US","secType":"STK","nameCN":"CITIUS ONCOLOGY INC","latestPrice":0.541,"timestamp":1774555199999,"preClose":0.578,"halted":0,"volume":188792,"delay":0,"changeRate":-0.0640138408304497,"floatShares":12321000,"shares":88275200,"eps":-0.305988,"marketStatus":"盘后交易","change":-0.037,"latestTime":"03-26 16:00:19 EDT","open":0.58,"high":0.58,"low":0.52,"amount":101216.5452216,"amplitude":0.103806,"askPrice":0.56,"askSize":100,"bidPrice":0.53,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-0.305988,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1774569600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.578,"preHourTrading":{"tag":"盘前","latestPrice":0.5904,"preClose":0.578,"latestTime":"08:55 EDT","volume":26,"amount":15.3504,"timestamp":1774529745780,"change":0.0124,"changeRate":0.021453,"amplitude":0},"volumeRatio":0.840508},"requestUrl":"/m/hq/s/CTOR","defaultTab":"news","newsList":[{"id":"1119011859","title":"Citius Oncology公布Lymphir™联合帕博利珠单抗治疗复发或难治性妇科癌研究者发起的1期研究积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1119011859","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119011859?lang=zh_cn&edition=full","pubTime":"2026-03-10 20:48","pubTimestamp":1773146891,"startTime":"0","endTime":"0","summary":"Citius Oncology宣布，其Lymphir™联合帕博利珠单抗治疗复发或难治性妇科癌的研究者发起1期临床试验获得了积极的顶线结果。该研究旨在评估该联合疗法的安全性、耐受性及初步疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CTXR","CTOR"],"gpt_icon":0},{"id":"1100741136","title":"Citius Oncology Inc一期临床试验显示：总体缓解率达86%，完全缓解率57%，部分缓解率29%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100741136","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100741136?lang=zh_cn&edition=full","pubTime":"2026-03-04 22:17","pubTimestamp":1772633851,"startTime":"0","endTime":"0","summary":"生物制药公司Citius Oncology Inc近日公布其一期临床试验数据，结果显示患者总体缓解率（ORR）达到86%。其中完全缓解（CR）比例为57%，部分缓解（PR）比例为29%。该数据凸显了其在研疗法的潜在疗效。\n临床试验采用分阶段设计，针对特定适应症患者群体进行评估。研究人员观察到治疗组在主要终点指标上表现突出，安全性数据亦符合预期标准。这些初步结果将为后续临床开发策略提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"1126885841","title":"Lymphir在I期研究中耐受性良好，未观察到剂量限制性毒性","url":"https://stock-news.laohu8.com/highlight/detail?id=1126885841","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126885841?lang=zh_cn&edition=full","pubTime":"2026-03-04 22:16","pubTimestamp":1772633804,"startTime":"0","endTime":"0","summary":"在CITIUS ONCOLOGY INC（简称CTOR）开展的I期临床研究中，其候选药物Lymphir展现出良好的安全性与耐受性。研究结果显示，在整个试验过程中，未观察到任何剂量限制性毒性事件，为后续临床开发奠定了坚实基础。这一积极数据进一步增强了该药物在肿瘤治疗领域的应用潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4139"],"gpt_icon":0},{"id":"1158577391","title":"Citius Oncology公布Lymphir™（E7777）在高危弥漫性大B细胞淋巴瘤商用CAR-T疗法前给药的1期研究初步顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1158577391","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158577391?lang=zh_cn&edition=full","pubTime":"2026-03-04 22:16","pubTimestamp":1772633771,"startTime":"0","endTime":"0","summary":"Citius Oncology, Inc. 宣布了其针对高危弥漫性大B细胞淋巴瘤患者的研究初步顶线数据。该1期临床试验旨在评估Lymphir™（研发代码E7777）在商用嵌合抗原受体T细胞疗法之前给药的安全性与初步疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"1122767016","title":"Citius Oncology与Uniphar达成独家协议 将淋巴瘤药物Lymphir™分销版图扩展至欧盟","url":"https://stock-news.laohu8.com/highlight/detail?id=1122767016","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122767016?lang=zh_cn&edition=full","pubTime":"2026-02-11 21:03","pubTimestamp":1770815018,"startTime":"0","endTime":"0","summary":"生物制药企业Citius Oncology宣布与欧洲领先医疗产品服务商Uniphar签署独家分销协议，正式将其创新淋巴瘤疗法Lymphir™的商业化版图拓展至欧盟市场。\n此次合作将依托Uniphar在欧洲建立的成熟分销网络，加速Lymphir™在欧盟地区的准入进程。该协议不仅强化了Citius Oncology的全球化战略布局，也为欧洲患者提供了更前沿的治疗选择。\nLymphir™作为针对特定淋巴瘤亚型的靶向疗法，此前已在部分国际市场展现出临床潜力。通过本次渠道拓展，Citius Oncology有望进一步提升其在肿瘤治疗领域的国际影响力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","BK4007","BK4139","CTOR"],"gpt_icon":0},{"id":"2606759209","title":"Citius Oncology, Inc.盘中异动 早盘股价大跌5.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606759209","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606759209?lang=zh_cn&edition=full","pubTime":"2026-01-27 22:33","pubTimestamp":1769524383,"startTime":"0","endTime":"0","summary":"北京时间2026年01月27日22时33分，Citius Oncology, Inc.股票出现异动，股价快速下挫5.42%。Citius Oncology, Inc.股票所在的制药行业中，整体涨幅为0.50%。其相关个股中，苏轩堂、Flora Growth Corp.、Apimeds Pharmaceuticals Us, Inc.涨幅较大，苏轩堂、Akanda Corp.、Flora Growth Corp.较为活跃，换手率分别为28.60%、5.54%、4.19%，振幅较大的相关个股有Flora Growth Corp.、Akanda Corp.、苏轩堂，振幅分别为17.09%、8.40%、8.39%。Citius Oncology, Inc.公司简介：Citius Oncology Inc是一家专注于开发和商业化靶向肿瘤疗法的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012722330397a3a35c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012722330397a3a35c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FLGC","BK4139","CTOR","BK4539","ZSTK","BK4183"],"gpt_icon":0},{"id":"2603769320","title":"Citius Oncology, Inc.盘中异动 大幅拉升5.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603769320","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603769320?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:42","pubTimestamp":1768315358,"startTime":"0","endTime":"0","summary":"北京时间2026年01月13日22时42分，Citius Oncology, Inc.股票出现波动，股价急速上涨5.61%。Citius Oncology, Inc.股票所在的制药行业中，整体跌幅为0.43%。其相关个股中，Im Cannabis Corp.、Biofrontera Inc.、Citius Oncology, Inc.涨幅较大，Akanda Corp.、Gelteq Limited、苏轩堂较为活跃，换手率分别为14.79%、5.41%、4.31%，振幅较大的相关个股有脑再生科技、大自然药业、Biofrontera Inc.，振幅分别为16.55%、11.06%、10.04%。Citius Oncology, Inc.公司简介：Citius Oncology Inc是一家专注于开发和商业化靶向肿瘤疗法的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011322423897a1a7b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011322423897a1a7b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2601842432","title":"Citius Oncology, Inc.盘中异动 早盘急速下挫6.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601842432","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601842432?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:32","pubTimestamp":1767709948,"startTime":"0","endTime":"0","summary":"北京时间2026年01月06日22时32分，Citius Oncology, Inc.股票出现异动，股价急速跳水6.96%。Citius Oncology, Inc.股票所在的制药行业中，整体涨幅为0.33%。其相关个股中，Caring Brands, Inc.、Gelteq Limited、脑再生科技涨幅较大，Akanda Corp.、Redhill Biopharma Ltd、Cbdmd, Inc.较为活跃，换手率分别为14.13%、3.33%、0.81%，振幅较大的相关个股有Caring Brands, Inc.、脑再生科技、Akanda Corp.，振幅分别为8.86%、6.33%、5.22%。Citius Oncology, Inc.公司简介：Citius Oncology Inc是一家专注于开发和商业化靶向肿瘤疗法的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106223228953c16f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106223228953c16f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2595500753","title":"Citius Oncology, Inc.盘中异动 早盘大幅下挫5.31%报1.07美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595500753","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595500753?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:48","pubTimestamp":1767019725,"startTime":"0","endTime":"0","summary":"北京时间2025年12月29日22时48分，Citius Oncology, Inc.股票出现波动，股价大幅跳水5.31%。Citius Oncology, Inc.股票所在的制药行业中，整体涨幅为0.09%。其相关个股中，Caring Brands, Inc.、Akanda Corp.、脑再生科技涨幅较大，Akanda Corp.、大自然药业、Cbdmd, Inc.较为活跃，换手率分别为117.47%、6.59%、5.20%，振幅较大的相关个股有Caring Brands, Inc.、脑再生科技、Cbdmd, Inc.，振幅分别为31.25%、18.85%、11.78%。Citius Oncology, Inc.公司简介：Citius Oncology Inc 是一家专业制药公司，致力于开发和商业化针对未满足需求的重症监护产品，专注于肿瘤产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229224845a4868ab8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229224845a4868ab8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4183","CTOR","BK4139","CABR"],"gpt_icon":0},{"id":"1194721703","title":"Citius Oncology完成1800万美元的同时注册直接发行和私募配售，价格符合纳斯达克规则","url":"https://stock-news.laohu8.com/highlight/detail?id=1194721703","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194721703?lang=zh_cn&edition=full","pubTime":"2025-12-11 05:31","pubTimestamp":1765402278,"startTime":"0","endTime":"0","summary":"Citius Oncology完成1800万美元的同时注册直接发行和私募配售，价格符合纳斯达克规则","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"1186772713","title":"Citius Oncology Inc - 直接发行以每股1.09美元购买1,284,404股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1186772713","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186772713?lang=zh_cn&edition=full","pubTime":"2025-12-09 21:33","pubTimestamp":1765287209,"startTime":"0","endTime":"0","summary":"Citius Oncology Inc - 直接发行以每股1.09美元购买1,284,404股普通股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR","CTXR","BK4007"],"gpt_icon":0},{"id":"1111513577","title":"Citius Oncology 宣布以市场定价进行1800万美元的注册直销及私人投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1111513577","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111513577?lang=zh_cn&edition=full","pubTime":"2025-12-09 21:31","pubTimestamp":1765287103,"startTime":"0","endTime":"0","summary":"Citius Oncology 宣布以市场定价进行1800万美元的注册直销及私人投资","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4007","CTXR","BK4139"],"gpt_icon":0},{"id":"1178681935","title":"Citius Oncology通过与Er-Kim的独家协议扩展Lymphir™在土耳其和中东国家的分销","url":"https://stock-news.laohu8.com/highlight/detail?id=1178681935","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178681935?lang=zh_cn&edition=full","pubTime":"2025-12-04 21:37","pubTimestamp":1764855430,"startTime":"0","endTime":"0","summary":"Citius Oncology通过与Er-Kim的独家协议扩展Lymphir™在土耳其和中东国家的分销","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTXR","BK4139","CTOR"],"gpt_icon":0},{"id":"1108685707","title":"Citius Oncology 宣布 Lymphir™ 上市，作为切肤性 T 细胞淋巴瘤的新型癌症免疫疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1108685707","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108685707?lang=zh_cn&edition=full","pubTime":"2025-12-02 01:01","pubTimestamp":1764608490,"startTime":"0","endTime":"0","summary":"Citius Oncology 宣布在美国商业化推出 Lymphir™，这是一种针对切肤性 T 细胞淋巴瘤的新型癌症免疫疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR","CTXR","BK4007"],"gpt_icon":0},{"id":"2585127830","title":"Citius Oncology, Inc.盘中异动 急速上涨5.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585127830","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585127830?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:30","pubTimestamp":1763735424,"startTime":"0","endTime":"0","summary":"北京时间2025年11月21日22时30分，Citius Oncology, Inc.股票出现波动，股价急速上涨5.62%。Citius Oncology, Inc.股票所在的制药行业中，整体涨幅为0.00%。其相关个股中，Shuttle Pharmaceuticals Holdings, Inc.、Scilex Holding Company C/Wts 10/11/2027 、Citius Oncology, Inc.涨幅较大，Shuttle Pharmaceuticals Holdings, Inc.、Inmed Pharmaceuticals Inc.、Citius Oncology, Inc.较为活跃，换手率分别为170.12%、3.94%、1.49%，振幅较大的相关个股有Citius Oncology, Inc.、Scynexis, Inc.、Inmed Pharmaceuticals Inc.，振幅分别为4.42%、2.49%、2.36%。Citius Oncology, Inc.公司简介：Citius Oncology Inc 是一家专业制药公司，致力于开发和商业化针对未满足需求的重症监护产品，专注于肿瘤产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511212230259777da73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511212230259777da73&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CTOR","BK4139"],"gpt_icon":0},{"id":"1149323781","title":"Citius Oncology与麦克森签署美国分销协议以支持Lymphir™商业推广","url":"https://stock-news.laohu8.com/highlight/detail?id=1149323781","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149323781?lang=zh_cn&edition=full","pubTime":"2025-10-20 20:37","pubTimestamp":1760963831,"startTime":"0","endTime":"0","summary":"Citius Oncology与麦克森签署美国分销协议以支持Lymphir™商业推广","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314106906.USD","LU1430594728.SGD","LU2089984988.USD","LU0122379950.USD","LU0048573561.USD","LU1506573853.SGD","BK4007","LU1037948897.HKD","LU2468319806.SGD","LU0861579265.USD","BK4175","BK4588","LU0203345920.USD","LU1023059063.AUD","LU2112291526.USD","LU0965509101.SGD","CTOR","LU1934455194.USD","LU0742534661.SGD","LU1983260115.SGD","LU0251142724.SGD","LU0868494708.USD","LU2324357040.USD","LU1366192091.USD","LU1814569148.SGD","LU1934455277.USD","LU0203347892.USD","BK4585","LU1057294990.SGD","CTXR","LU1934455863.HKD","BK4139","LU0965508806.USD","BK4533","MCK","LU0942090050.USD","LU0251131958.USD","LU0868494617.USD","LU0965509010.AUD","LU0432979614.USD","LU0965509283.SGD","LU1061106388.HKD","LU1585245621.USD","LU1037948541.HKD"],"gpt_icon":0},{"id":"1125386068","title":"Citius Oncology与Eversana签订独家商业化协议，助力计划于2025年第四季度推出Lymphir™","url":"https://stock-news.laohu8.com/highlight/detail?id=1125386068","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125386068?lang=zh_cn&edition=full","pubTime":"2025-10-16 20:48","pubTimestamp":1760618892,"startTime":"0","endTime":"0","summary":"Citius Oncology与Eversana签订独家商业化协议，助力计划于2025年第四季度推出Lymphir™","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","BK4007","BK4139","CTOR"],"gpt_icon":0},{"id":"2518273720","title":"Citius Oncology, Inc.盘中异动 股价大跌8.51%报0.860美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518273720","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518273720?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:19","pubTimestamp":1741616395,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时19分，Citius Oncology, Inc.股票出现异动，股价大幅跳水8.51%。截至发稿，该股报0.860美元/股，成交量1.9481万股，换手率0.03%，振幅3.23%。Citius Oncology, Inc.股票所在的制药行业中，整体跌幅为1.96%。Citius Oncology, Inc.公司简介：Citius Oncology Inc 是一家专业制药公司，致力于针对肿瘤产品未满足需求的重症护理产品的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022195598a2a913&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022195598a2a913&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2517803941","title":"Citius Oncology, Inc.盘中异动 快速拉升6.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517803941","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517803941?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:18","pubTimestamp":1741191502,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日00时18分，Citius Oncology, Inc.股票出现异动，股价快速上涨6.42%。Citius Oncology, Inc.股票所在的制药行业中，整体涨幅为0.30%。其相关个股中，Organogenesis Holdings Inc.、坎伯兰药业、Quantum Biopharma Ltd.涨幅较大，Painreform Ltd.、Petros Pharmaceuticals, Inc.、Quantum Biopharma Ltd.较为活跃，换手率分别为16.67%、10.66%、5.48%，振幅较大的相关个股有坎伯兰药业、Alpha Teknova, Inc.、Medicus Pharma Ltd.，振幅分别为27.93%、16.89%、14.66%。Citius Oncology, Inc.公司简介：Citius Oncology Inc 是一家专业制药公司，致力于针对肿瘤产品未满足需求的重症护理产品的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306001822989d5f04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306001822989d5f04&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2516082026","title":"Citius Oncology, Inc.盘中异动 早盘股价大涨6.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516082026","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516082026?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:09","pubTimestamp":1741100966,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时09分，Citius Oncology, Inc.股票出现异动，股价快速拉升6.73%。Citius Oncology, Inc.股票所在的制药行业中，整体跌幅为0.13%。其相关个股中，Evoke Pharma, Inc.、Esperion Therapeutics, Inc.、Citius Oncology, Inc.涨幅较大，大自然药业、Emergent Biosolutions Inc.、Petros Pharmaceuticals, Inc.较为活跃，换手率分别为4.87%、4.06%、2.73%，振幅较大的相关个股有Therapeuticsmd, Inc.、Evoke Pharma, Inc.、Emergent Biosolutions Inc.，振幅分别为18.05%、15.18%、13.76%。Citius Oncology, Inc.公司简介：Citius Oncology Inc 是一家专业制药公司，致力于针对肿瘤产品未满足需求的重症护理产品的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304230926989bb701&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304230926989bb701&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CTOR","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.citiusonc.com","stockEarnings":[{"period":"1week","weight":-0.1525},{"period":"1month","weight":-0.493},{"period":"3month","weight":-0.4952},{"period":"6month","weight":-0.711},{"period":"1year","weight":-0.272},{"period":"ytd","weight":-0.422}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":-0.0375},{"period":"3month","weight":-0.0486},{"period":"6month","weight":-0.0076},{"period":"1year","weight":0.1414},{"period":"ytd","weight":-0.0368}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Citius Oncology, Inc.（前身为TenX Keane Acquisition）于2021年3月1日在开曼群岛注册成立，并于2024年8月5日作为特拉华州公司迁移并归化。Citius Oncology将作为一个平台，开发和商业化新型靶向肿瘤疗法。2024年8月，其主要资产LYMPHIR获得FDA批准，用于治疗至少接受过一次全身治疗的复发或难治性CTCL成人患者。","yearOnYearQuotes":[{"month":1,"riseRate":1,"avgChangeRate":0.027634},{"month":2,"riseRate":0.75,"avgChangeRate":0.015537},{"month":3,"riseRate":0.5,"avgChangeRate":-0.173567},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.017645},{"month":5,"riseRate":1,"avgChangeRate":0.020372},{"month":6,"riseRate":0.666667,"avgChangeRate":1.280036},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.177544},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.282178},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.091201},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.091127},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.146553},{"month":12,"riseRate":0.666667,"avgChangeRate":-0.005673}],"exchange":"NASDAQ","name":"CITIUS ONCOLOGY INC","nameEN":"CITIUS ONCOLOGY INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CITIUS ONCOLOGY INC(CTOR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供CITIUS ONCOLOGY INC(CTOR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"CITIUS ONCOLOGY INC,CTOR,CITIUS ONCOLOGY INC股票,CITIUS ONCOLOGY INC股票老虎,CITIUS ONCOLOGY INC股票老虎国际,CITIUS ONCOLOGY INC行情,CITIUS ONCOLOGY INC股票行情,CITIUS ONCOLOGY INC股价,CITIUS ONCOLOGY INC股市,CITIUS ONCOLOGY INC股票价格,CITIUS ONCOLOGY INC股票交易,CITIUS ONCOLOGY INC股票购买,CITIUS ONCOLOGY INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CITIUS ONCOLOGY INC(CTOR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供CITIUS ONCOLOGY INC(CTOR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}